IP Library Granted Patent US 9,910,052
Granted Patent B2
US 9,910,052 · App. 14/398,971 · Granted Mar 6, 2018

Method of diagnosing and treating infectious disseminated intravascular coagulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,910,052
App. No.
14/398,971
Granted
Mar 6, 2018
Kind
B2
Abstract

Markers useful in diagnosing disseminated intravascular coagulation (DIC) or infectious DIC are provided. In a method for detecting DIC of the present invention, sCD14-ST in a sample is measured. In a method of detecting infectious DIC of the present invention, sCD14-ST and a coagulation-related marker in a sample are measured.

Claims (14)

1. A method of diagnosing and treating infectious disseminated intravascular coagulation, comprising the steps of:

(A) measuring soluble Cluster of Differentiation 14 subtype (sCD14-ST) in a sample collected from a patient suspected of having disseminated intravascular coagulation, or a patient suffering from disseminated intravascular coagulation;

(B) judging that the patient suffers from disseminated intravascular coagulation when an sCD14-ST value is higher than that of a non-disseminated-intravascular-coagulation patient; and

(C) administering an appropriate treatment to the patient for infectious disseminated intravascular coagulation.

2. The method according to claim 1 , wherein the sCD14-ST value is compared in the judgment step to a threshold previously determined.

3. The method according to claim 1 , wherein sCD14-ST is measured by an immunoassay.

4. The method according to claim 1 , comprising measuring a coagulation-related marker in a sample in addition to sCD14-ST.

5. A method of diagnosing and treating infectious disseminated intravascular coagulation, comprising the steps of:

(A) measuring soluble Cluster of Differentiation 14 subtype (sCD14-ST) and a coagulation-related marker in a sample collected from a patient suspected of having infectious disseminated intravascular coagulation, or a patient suffering from infectious disseminated intravascular coagulation, and

(B) judging that the patient suffers from infectious disseminated intravascular coagulation when an sCD14-ST value and a coagulation-related marker value are changed in comparison with those of a non-infectious-disseminated-intravascular-coagulation patient; and

(C) administering an appropriate treatment to the patient for infectious disseminated intravascular coagulation.

6. The method according to claim 5 , wherein the sCD14-ST value and the coagulation-related marker value are compared in the judgment step to thresholds previously determined, respectively.

7. The method according to claim 5 , wherein the coagulation-related marker is at least one selected from the group consisting of D-dimer, fibrin/fibrinogen degradation products (FDP), thrombin-antithrombin III complex, platelet counts, and protein C.

8. The method according to claim 5 , wherein sCD14-ST is measured by an immunoassay.

Assignments (4)
CHANGE OF ADDRESS Recorded Feb 25, 2024
From: LSI MEDIENCE CORPORATION
To: LSI MEDIENCE CORPORATION
Reel/Frame 066674/0958 →
COMPANY SPLIT Recorded Feb 25, 2024
From: LSI MEDIENCE CORPORATION
To: PHC CORPORATION
Reel/Frame 066675/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2021
From: FUKUOKA UNIVERSITY
To: LSI MEDIENCE CORPORATION
Reel/Frame 056953/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2014
From: ISHIKURA, HIROYASU
To: LSI MEDIENCE CORPORATION; FUKUOKA UNIVERSITY
Reel/Frame 034109/0740 →